Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study

Administration of IV-golimumab 2 mg/kg improves fatigue symptoms in axial spondylitis in a 52 Week study. At Week 16 of treatment, improvements in ASAS, ASDAS, BASDAI and SF-36 scores were observed at week 16 of treatment.

This post-hoc analysis of the GO-ALIVE study specifically investigates fatigue symptoms related to AxSpA. Participants were randomised 1:1 to golimumab or a placebo, with the placebo group introduced to golimumab in Week 16. The placebo group had similar improvements to the treatment group at Week 52.